Cite
APA Citation
Loriot, Y., Necchi, A., Park, S. H., Huddart, R. A., Burgess, E., Zhong, B., Santiago-Walker, A., Little, S., Roccia, T., De Porre, P., & Siefker-Radtke, A. O. (n.d.). 920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095323481.0x000039